Tiziana Life Sciences Ltd · NASDAQ:TLSA
Tiziana Life Sciences — IPO Roadshow (December 2025)
21 slides from Tiziana Life Sciences's IPO roadshow presentation, Dec 12, 2025
Slide 1: Intranasal Fully Human Anti-CD3 mAb (Foralumab) Therapy
Intranasal Fully Human Anti - CD3 mAb (“FORALUMAB”) Therapy to Enable Breakthroughs in Neuroinflammatory and Neurodegenerative Diseases Nasdaq: TLSA
Slide 2: Disclaimers
Disclaimers This presentation is made solely for information purposes and no representation or warranty, express or implied, is made by Tiziana Life Sciences Ltd. ("Tiziana," "we," "us," "our," and, together with our subsidiaries, the "Company") or any of its representatives as to the information co
Slide 3: Disclaimers, Cont'd
3 Disclaimers, Cont’d This presentation also contains estimates, projections and other information concerning our industry and our business, including data regarding the estimated size of our markets and their projected growth rates. Unless otherwise indicated, such estimates, projections and other
Slide 4: Foralumab: Mechanism of Action
CD4 + FoxP3 + Treg Patient inhales the antibody intranasally Binding of foralumab to the T - cell receptor complex in cervical lymph node Tregs are then c reated and activated These created Tregs then cross the blood brain barrier and regulate the activated innate immune system (microglia). Intranas
Slide 5: Non-active Secondary Progressive Multiple Sclerosis (na-SPMS)
Non - active Secondary Progressive Multiple Sclerosis ( na - SPMS)
Slide 6: Non-Active Secondary Progressive Multiple Sclerosis is an Attractive Market
4 Non - Active Secondary Progressive Multiple Sclerosis is an Attractive Market Sources: * Vasanthaprasad et al. BMC Neurology (2022) 22:301 ** Tjalf Ziemssen , et. al Neurol Neuroimmunol Neuroinflamm . 2023 Jan; 10(1): e200064; # Ocrevus global sales reported by Roche as CHF 8.4 billion CHF in 2023
Slide 7: Intranasal Foralumab Reduces Neuroinflammation EA6
5 Intranasal Foralumab Reduces Neuroinflammation EA6
Slide 8: Improvement or Stabilization in all na-SPMS Expanded Access Patients
6 Improvement or Stabilization in all na - SPMS Expanded Access Patients Preprint Paper Online on MedRxiv and submitted for peer review May 2025 • Clinical improvements or stabilization was reported across the entire group, as measured by Fatigue scores (MFIS), T25FW, EDSS, or Pyramidal Scores • Fat
Slide 9: Non-Active SPMS Phase 2a Study Design
7 Intranasal Foralumab Dosing (n=54); Double - Blind, Placebo - Controlled, 18 Patients Per Treatment Arm Non - Active Secondary Progressive MS: Phase 2a Study Design: Each Cycle = 3 Weeks / 4 cycles x 3 = 12 weeks Baseline Screening Week 1 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 W
Slide 10: Multiple System Atrophy (MSA)
Multiple System Atrophy (MSA)
Slide 11: Multiple System Atrophy Phase 2a Clinical Trial
9 Multiple System Atrophy (MSA) Phase 2a Clinical Trial Classified as Orphan disease by the FDA No FDA approved treatments available Similar symptoms to Parkinson’s disease so often misdiagnosed FDA Approved IND Q3 2025 First patient dosed in August 2025 and will assess microglial activation and MSA
Slide 12: Early Symptomatic & Moderate Alzheimer's Disease (AD)
Early Symptomatic & Moderate Alzheimer’s Disease (AD)
Slide 13: Alzheimer's Disease Program is Advancing
11 Alzheimer’s Disease Program is Advancing and Equally Exciting Letter to Proceed received for IND to conduct a Phase 2 study of intranasal foralumab in Alzheimer’s disease patients Phase 2 trial for Early Symptomatic Alzheimer’s Disease planned to start H2 2025 and will assess microglial activatio
Slide 14: Moderate Alzheimer's Disease Expanded Access Study
12 Moderate Alzheimer’s Disease Expanded Access Study • 78 - Year - Old Moderate Alzheimer’s patient treated for 3 months with intranasal foralumab • PET Scan shows significant reduction of microglia activity following 3 months of treatment • Data presented at AD/PD in April 2025 • Data Published in
Slide 15: Early Symptomatic Alzheimer's Disease Phase 2a Study Design
13 Intranasal Foralumab Dosing (n=32); Double - Blind, Placebo - Controlled, 2 Clinical Sites Treatment Arms Per Site: 6 x 50mcg, 6 x 100mcg, 4 x Placebo. Early Symptomatic Alzheimer’s Disease: Phase 2a Study Design: Each Cycle = 3 Weeks / 4 cycles x 3 = 12 Week readout Baseline Screening Week 1 Wee
Slide 16: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Slide 17: ALS Phase 2 Study Supported by The ALS Association
15 ALS Phase 2 Study Supported by The ALS Association Global Market size of $790m CARG of 5.8% from 2024 - 2030 $1.38bln by 2035 IND Filed March 2025 Phase 2 trial planned to start H2 2025 and will assess microglial activation Grant Awarded from The ALS Association to Study Intranasal Foralumab in A
Slide 18: ALS Phase 2a Study Design
16 Intranasal Foralumab Dosing (n=24); Randomized, Placebo Controlled Trial ALS: Phase 2a Study Design: Each Cycle = 3 Weeks / 4 cycles x 3 = 12 week readout / 4 cycles x 6 = 24 week readout Baseline Screening Week 1 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 11 Week 12 50 mcg 100 mcg Pl
Slide 19: Intranasal Foralumab Pipeline
17 Intranasal Foralumab Pipeline Phase 3 Phase 2 Expanded Access Program Phase 1 IND Preclinical Expecting Topline Data 1H 2026 Non - Active Secondary Progressive Multiple Sclerosis Phase 2 Study Began dosing Aug 2025 Multiple System Atrophy (MSA) Phase 2 Study Expected 2H 2025 Start Alzheimer’s Dis
Slide 20: Tiziana Cap Table – December 2025
18 Tiziana Cap Table – December 2025 120,207,401 Outstanding shares 7,510,702 WAEP $0.92 Outstanding options 126,316 WAEP $1.50 Outstanding Warrants 4,200,000 Outstanding restricted stock units
Slide 21: US and UK Headquarters Contact Details
US Headquarters (Boston) Tiziana Life Sciences Ltd. 535 Boylston Street, Floor 8 Boston, MA 02116 UK Headquarters (London) Tiziana Life Sciences plc 14 - 15 Conduit Street London W1D 2XJ Investors: +44 (0)207 495 2379 info @tizianalifesciences.com Nasdaq: TLSA